Opinion
Video
Author(s):
Following ASH 2023, Andrew Brunner, MD, reviews key updates from the COMMANDS trial investigating frontline luspatercept in patients with lower-risk MDS.
Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia
Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy
Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML
Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups
FDA Grants Priority Review to Tabelecleucel for Adult/Pediatric EBV+ Post-Transplant Lymphoproliferative Disease
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium